drugset
drugset / Trial / NCT05667194

Phase 1 Trial of KH617

NCT05667194 ↗

Phase 1 Recruiting 45 enrolled Sichuan Honghe Biotechnology Co., Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

KH617 is a injection used for advanced solid tumors which must be diluted with 5% Dextrose Injection.

Timeline

Start
2022-12-26
Primary completion
2030-09
Completion
2031-08

Drugs

EvaluationDrugModalityDoseRoute
Subject KH617 Unknown — Other

Indications

cancer